-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target

Benzinga·10/02/2026 14:50:29
语音播报
Wedbush analyst David Nierengarten reiterates Aktis Oncology (NASDAQ:AKTS) with a Outperform and maintains $35 price target.